Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz3. fázis

A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 Years

A legfontosabb adatok

Ki végzi
National Vaccine and Serum Institute, China
Hol
Kína8 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Fázis
3. fázis
Résztvevők
13 500 fő, tervezett
Kezdés
2022. jún. 4.
Várható befejezés
2028. jún.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
  • placebo
A regiszteradat frissítve
2026. október 28.

Ki vehet részt

Életkor
18 év – 45 év
Nem
Csak nők
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 34 feltétel megnézéseKevesebb

Ki vehet részt

  • non-gynecological related
  • *Chinese women with a history of sexual life who are 18-45 years old at the time of enrollment and can provide legal identification
  • *Axillary body temperature <37.3℃ on the day of enrollment
  • The subjects themselves have the ability to understand the clinical trial and voluntarily sign the informed consent
  • Subjects have the ability to read, understand, and fill out research application forms such as diary cards/contact cards, and promise to follow the research requirements participate in follow-up visits
  • No previous HPV vaccination history, no commercially available HPV vaccine during the study period (about 6 years after enrollment) plan of
  • The subject has a negative urine pregnancy test on the day before vaccination; Gynecology related
  • *Effective contraception was taken from day 1 of last menstrual cycle to day 0 of the study, and no childbearing within 7 months after enrollment plan
  • *Before the gynecological visit and within 48 hours before any subsequent visit that includes a gynecological sample collection: asexual life (including same-sex or opposite-sex anal, vaginal or genital contact), unwashed/washed vagina (Except for normal bathing outside the vagina), no vaginal drugs or preparations are used

Ki nem vehet részt

  • *3 months prior to vaccination or planned to receive any immune globulin or blood products within 7 months of enrollment
  • *Received any vaccine within 14 days prior to vaccination, or received live vaccine within 28 days
  • *3 days before vaccination, suffering from acute febrile illness (body temperature ≥38.5℃) or using antipyretic, analgesic and antiallergic drugs (eg: acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.)
  • 1 month before vaccination or plan to receive immunosuppressive therapy within 7 months after enrollment, such as oral administration for more than 2 consecutive weeks Oral or injectable systemic corticosteroid therapy (≥2 mg/kg/day or ≥20 mg/day prednisone or equivalent to prednisone) amount); however, topical medications (such as ointments, eye drops, inhalers, or nasal sprays) are not limited
  • Previous splenectomy or impaired spleen function
  • Those with previous or current severe liver, kidney and cardiovascular diseases, complicated diabetes, and malignant tumors
  • Participate in other clinical studies (drugs, vaccines and medical devices) within 3 months before vaccination or during the planned study period
  • *Pregnant, breastfeeding, or within 6 weeks of pregnancy at the time of the first dose of the vaccine
  • Previous history of abnormal cervical cancer screening or lesions (including HPV DNA positive, squamous intraepithelial lesion (SIL)or atypical squamous cells of undetermined significance (ASC-US), atypical squamous epithelial cells - excluding high-grade squamous cells Intraepithelial lesions (ASC-H), atypical glandular cells (AGC) or with cervical intraepithelial neoplasia (CIN),Adenocarcinoma in situ (AIS) or cervical cancer, etc.)
  • Previous hysterectomy or pelvic radiation therapy or severe cervical/vaginal dysplasia
  • If any of the following occurs, the investigator will terminate the subject's vaccination with the investigational vaccine
  • History of severe allergies/conditions requiring medical intervention (e.g. Anaphylactic shock, anaphylactic laryngeal edema, anaphylactoid purpura, thrombocytopenic purpura, local allergic necrosis(Arthus reaction) etc.)
  • Immunocompromised or diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia Blood disease, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammation STD or other autoimmune disease
  • Have a history of epilepsy, convulsions, mental illness or a family history of mental illness
  • Suffering from thrombocytopenia or any coagulation disorder that can become a contraindication to intramuscular injection
  • *Acute lower genital tract infection (such as acute vulvitis/vaginitis/cervicitis, etc.) found by the naked eye during gynecological examination
  • Past or current anal and genital diseases (such as vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts,vulvar cancer, vaginal cancer and anal cancer, etc.)
  • First dose exclusion criteria:
  • (Visits may be rescheduled if the criteria described in the "*" option are met at screening)
  • Non-gynecological related
  • * Those with abnormal blood pressure (systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg) on physical examination before vaccination
  • The investigator believes that the subject has any other factors that are not suitable for participating in the clinical trial (such as: poor compliance or planning Permanent relocation from the area before the study is completed, etc.); Gynecology related
  • *The subject is in the menstrual period
  • Meet the first dose exclusion criteria 5, 6, 7, 8, 9, 12
  • Any other reasons that, in the judgment of the investigator, warrant discontinuation of the investigational vaccination

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

A total of 13500 Chinese women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 35-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or placebo according to the 0, 2, and 6 months immunization program.

A vizsgálat 2 csoportja

  • experiment groupA vizsgált kezelés

    According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine

    Kezelés: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

  • placeboPlacebo, összehasonlításként

    According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multicenter Randomized, Blinded, Placebo-controlled Phase III Clinical Trial Evaluating the Protective Efficacy, Safety and Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 Years
A regiszteradat frissítve
2026. október 28.